PubMed Health⌕ Search

Biomedical subjects

L J Santiago

Publications and source records attributed to L J Santiago.

2 recordsLinked to original sources

High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions.

Dextromethorphan (DM), a non-narcotic antitussive with anticonvulsant activity, binds to high (Kd, 57 nM)- and low-affinity sites (Kd, 24 microM) in the guinea pig brain. This work, done at physiological pH, expands previous results obtained at pH 8.3. Phenytoin (PHT) produces an allosteric increase in the binding of [3H]DM, which is more marked than that reported previously: PHT (100 microM,) at pH 7.4, increased the binding affinity of [3H]DM to brain homogenates 4-fold, without changing the concentration of DM sites. Moreover, ropizine (SC-13504) an anticonvulsant benzhydryl piperazine, also produced a marked concentration-dependent increase in the binding of [3H]DM, which is mediated by a decrease in the dissociation rate of [3H]DM. Importantly, the effects of ropizine are fully apparent at 10 microM, 10-fold lower than those of PHT. The effects of PHT and ropizine show that the affinity of the DM sites can be increased by other ligands, suggesting that these sites are located on macromolecules that can exist in at least two conformational states. [3H]DM also binds to peripheral tissues, but the brain displays the highest affinity. Besides, the central and peripheral sites are different as determined by competition studies with caramiphen and carbetapentane, which are DM site ligands with antitussive and anticonvulsant activity. The results reported in this communication are consistent with the hypothesis that the high-affinity DM binding sites mediate antitussive and anticonvulsant activity when occupied by the appropriate ligand.

Animals↗

Allosteric modulation of dextromethorphan binding sites.

The nonopioid antitussives dextromethorphan (DM), carbetapentane and caramiphen are efficacious anticonvulsant agents in the rat MES test. The findings presented strongly suggest the existence of a novel allosteric mechanism by which drugs acting at two different but interacting sites, exert their effects. This mechanism has marked similarities with the gamma-aminobutyric acid (GABA)-benzodiazepine interactions, even though their binding sites are different. The allosteric interactions of dextromethorphan and phenytoin in the binding assay and the potentiation of the anticonvulsant effects of phenytoin by dextromethorphan suggest that drugs that bind to the dextromethorphan sites could be used to reduce the effective dose of phenytoin and reduce its side effects, at least those which are not an extension of its specific pharmacological actions. It is evident that the investigation of the molecular mechanisms described may help to open new approaches to understand and treat convulsive disorders, to find novel anticonvulsant drugs and to further explain some of the molecular mechanisms of neuronal excitability.

Animals↗